Abstract
Myelosuppression secondary to chemotherapy remains a serious adverse effect of cancer therapy that causes high morbidity and mortality. Several current European and American guidelines recommend consideration of primary prophylaxis with colony-stimulating factors (CSFs) when the risk of febrile neutropenia is higher than 20 %. The main factors associated with a high risk of febrile neutropenia include the chemotherapy regimen, tumor type, and patient-related factors such as old age and/or comorbidities. The purpose of this paper is to summarize the most relevant clinical trials and updated recommendations of the main guidelines on the role of granulocyte colony-stimulating factors (G-CSFs) in febrile neutropenia, examining whether the combination of G-CSF with chemotherapy improves overall survival. Future directions for G-CSF use are also discussed.
Similar content being viewed by others
References
Fortner BV, Houts AC, Schwartzberg LS (2006) A prospective investigation of chemotherapy-induced neutropenia and quality of life. J Support Oncol 4:472–478
Padilla G, Ropka ME (2005) Quality of life and chemotherapy-induced neutropenia. Cancer Nurs 28:167–171
Lyman GH, Kuderer NM (2003) Epidemiology of febrile neutropenia. Support Cancer Ther 1:23–35. doi:10.3816/SCT.2003.n.002
Timmer-Bonte JN, de Boo TM, Smit HJ et al (2005) Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 23:7974–7984. doi:10.1200/JCO.2004.00.7955
Bonadonna G, Moliterni A, Zambetti M et al (2005) 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 330:217. doi:10.1136/bmj.38314.622095.8F
Lyman GH, Dale DC, Crawford J (2003) Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21:4524–4531. doi:10.1200/JCO.2003.05.002
Bonadonna G, Valagussa P, Moliterni A et al (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332:901–906. doi:10.1056/NEJM199504063321401
Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340
Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323–1332. doi:10.1056/NEJM199305063281808
Common Terminology Criteria for Adverse Events (CTCAE) v3.0 (2006) US National Cancer Institute. http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed Dec 2013
Common Terminology Criteria for Adverse Events (CTCAE).v4.0 (2010) Department of Health and Human Services, National Institutes of Health. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed Dec 2013
Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56–e93. doi:10.1093/cid/cir073
Hughes WT, Armstrong D, Bodey GP et al (1997) 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Inf Dis Soc Am Clin Infect Dis 25:551–573
Meza L, Baselga J, Holmes FA, Liang BBJ (2002) Incidence of febrile neutropenia (FN) is directly related to duration of severe neutropenia (DSN) after myelosuppressive chemotherapy. Proc Am Soc Clin Oncol 21:255b
Crawford J, Dale DC, Kuderer NM et al (2008) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 6:109–118
Aarts MJ, Peters FP, Mandigers CM et al (2013) Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. J Clin Oncol. doi:10.1200/JCO.2012.44.6229
Chen-Hardee S, Chrischilles EA, Voelker MD et al (2006) Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin’s lymphoma (United States). Cancer Causes Control 17:647–654. doi:10.1007/s10552-005-0502-4
National Comprehensive Cancer Network (2013) NCCN Clinical Practice Guideline in oncology myeloid growth factors. http://www.nccn.org. Accessed Dec 2013
Lyman GH, Lyman CH, Agboola O (2005) Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10:427–437. doi:10.1634/theoncologist.10-6-427
Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32
Choi MR, Solid CA, Chia VM et al (2014) Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy. Support Care Cancer 22:1619–1628. doi:10.1007/s00520-014-2121-7
Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051
Kuderer NM, Dale DC, Crawford J et al (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266. doi:10.1002/cncr.21847
Mayordomo JI, López A, Viñolas N et al (2009) Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin 25:2533–2542. doi:10.1185/03007990903209563
Wingard JR, Elmongy M (2009) Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics. Crit Rev Oncol Hematol 72:144–154. doi:10.1016/j.critrevonc.2009.01.003
Yoshida M, Ohno R (2004) Antimicrobial prophylaxis in febrile neutropenia. Clin Infect Dis 39(Suppl 1):S65–S67. doi:10.1086/383058
National Collaborating Centre for Cancer. NICE Clinical Guideline Evidence review (2012) Prevention and management of neutropenic sepsis in cancer patients. http://www.nice.org.uk/nicemedia/live/13905/61101/61101.pdf. Accessed Dec 2013
Kaushansky K (2006) Lineage-specific hematopoietic growth factors. N Engl J Med 354:2034–2045. doi:10.1056/NEJMra052706
Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205. doi:10.1200/JCO.2006.06.4451
Crawford J, Caserta C, Roila F (2010) Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 21(Suppl 5):v248–v251. doi:10.1093/annonc/mdq195
Chirivella I, Bermejo B, Insa A et al (2009) Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 114:479–484. doi:10.1007/s10549-008-0018-1
Bosly A, Bron D, Van Hoof A et al (2008) Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 87:277–283. doi:10.1007/s00277-007-0399-y
Jakobsen A, Berglund A, Glimelius B et al (2002) Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer. Acta Oncol 41:525–531
Radosavljevic D, Golubicic I, Gavrilovic D, et al. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer? J BUON 14:203–209
Neupogen (filgrastim). Thousand Oaks, CA: Amgen, (package insert) (2012). http://pi.amgen.com/united_states/neupogen/neupogen_pi_hcp_english.pdf. Accessed July 2013
Neulasta (pegfilgrastim). Thousand Oaks, CA: Amgen, (package insert) (2011). https://www.amgen.ca/Neulasta_PM.pdf. Accessed July 2013
European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) (2006) Guidelines on similar biological medicinal products containing biotechnology-derived proteins as active substance. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp&murl=menus/regulations/regulations.jsp&mid=WC0b01ac058002958c&jsenabled=true. Accessed Oct 2013
Gabrilove JL, Jakubowski A, Fain K et al (1988) Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 82:1454–1461. doi:10.1172/JCI113751
Trillet-Lenoir V, Green J, Manegold C et al (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319–324
Crawford J, Ozer H, Stoller R et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164–170. doi:10.1056/NEJM199107183250305
Yang B-B, Kido A, Shibata A (2007) Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy. Pharmacotherapy 27:1387–1393. doi:10.1592/phco.27.10.1387
Green MD, Koelbl H, Baselga J et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29–35
Holmes FA, O’Shaughnessy JA, Vukelja S et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727–731
Von Minckwitz G, Kümmel S, du Bois A et al (2008) Pegfilgrastim +/− ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 19:292–298. doi:10.1093/annonc/mdm438
Weycker D, Malin J, Kim J et al (2009) Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther 31:1069–1081. doi:10.1016/j.clinthera.2009.05.019
Cooper KL, Madan J, Whyte S et al (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404. doi:10.1186/1471-2407-11-404
Naeim A, Henk HJ, Becker L et al (2013) Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer 13:11. doi:10.1186/1471-2407-13-11
Weycker D, Hackett J, Edelsberg JS et al (2006) Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40:402–407. doi:10.1345/aph.1G516
Tjan-Heijnen VC, Biesma B, Festen J et al (1998) Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma. J Clin Oncol 16:2708–2714
Burris HA, Belani CP, Kaufman PA et al (2010) Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin’s lymphoma: results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract 6:133–140. doi:10.1200/JOP.091094
Zwick C, Hartmann F, Zeynalova S et al (2011) Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. Ann Oncol 22:1872–1877. doi:10.1093/annonc/mdq674
Hartmann LC, Tschetter LK, Habermann TM et al (1997) Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 336:1776–1780. doi:10.1056/NEJM199706193362502
Clark OAC, Lyman GH, Castro AA et al (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23:4198–4214. doi:10.1200/JCO.2005.05.645
Bohlius J, Herbst C, Reiser M, et al. (2008) Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane database Syst Rev CD003189. doi: 10.1002/14651858.CD003189.pub4
Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158–3167. doi:10.1200/JCO.2006.08.8823
Lyman GH, Dale DC, Wolff DA et al (2010) Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 28:2914–2924. doi:10.1200/JCO.2009.25.8723
Lyman GH, Dale DC, Culakova E et al (2013) The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24:2475–2484. doi:10.1093/annonc/mdt226
Dubois RW, Pinto LA, Bernal M et al (2004) Benefits of GM-CSF versus placebo or G-CSF in reducing chemotherapy-induced complications: a systematic review of the literature. Support Cancer Ther 2:34–41. doi:10.3816/SCT.2004.n.020
Lambertini M, Del Mastro L, Bellodi A, Pronzato P (2014) The five “Ws” for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). Crit Rev Oncol Hematol 89:112–128. doi:10.1016/j.critrevonc.2013.08.006
Veerappan R, Morrison M, Williams S, Variakojis D (2007) Splenic rupture in a patient with plasma cell myeloma following G-CSF/GM-CSF administration for stem cell transplantation and review of the literature. Bone Marrow Transplant 40:361–364. doi:10.1038/sj.bmt.1705736
Martin WG, Ristow KM, Habermann TM et al (2005) Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 23:7614–7620. doi:10.1200/JCO.2005.02.7243
Saxman SB, Nichols CR, Einhorn LH (1997) Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. Chest 111:657–660
Potosky AL, Malin JL, Kim B et al (2011) Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst 103:979–982. doi:10.1093/jnci/djr152
Krzemieniecki K, Sevelda P, Erdkamp F et al (2014) Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice. Support Care Cancer 22:667–677. doi:10.1007/s00520-013-2021-2
Sierra J, Szer J, Kassis J et al (2008) A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer 8:195. doi:10.1186/1471-2407-8-195
Koumakis G, Vassilomanolakis M, Barbounis V et al (1999) Optimal timing (preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide. Oncology 56:28–35
Scott SD, Chrischilles EA, Link BK et al. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin’s lymphoma treated with chemotherapy. J Manag Care Pharm 9:15–21
Lyman GH, Barron RL, Natoli JL, Miller RM (2012) Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. Crit Rev Oncol Hematol 81:296–308. doi:10.1016/j.critrevonc.2011.04.010
Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia. J Clin Oncol 21:1431–1439. doi:10.1200/JCO.2003.09.081
Bonilla L, Ben-Aharon I, Vidal L et al (2010) Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 102:1845–1854. doi:10.1093/jnci/djq409
Lee YM, Lockwood C (2013) Prognostic factors for risk stratification of adult cancer patients with chemotherapy-induced febrile neutropenia: a systematic review and meta-analysis. Int J Nurs Pract 19:557–576. doi:10.1111/ijn.12099
Gridelli C, Aapro MS, Barni S et al (2007) Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel. Crit Rev Oncol Hematol 63:53–64. doi:10.1016/j.critrevonc.2007.01.008
Lyman GH, Kuderer NM, Crawford J et al (2011) Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117:1917–1927. doi:10.1002/cncr.25691
Schnipper LE, Smith TJ, Raghavan D et al (2012) American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 30:1715–1724. doi:10.1200/JCO.2012.42.8375
Conflict of interest
S Cortés de Miguel has received an unrestricted research grant from Amgen, Inc. (Europe). MA Calleja-Hernández, S Menjón-Beltrán, and I Vallejo-Rodríguez have no other conflicts of interest. The interpretation and reporting of these data are the sole responsibility of the authors. All authors reviewed the paper and approved the final version.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cortés de Miguel, S., Calleja-Hernández, M.Á., Menjón-Beltrán, S. et al. Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia. Support Care Cancer 23, 547–559 (2015). https://doi.org/10.1007/s00520-014-2459-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-014-2459-x